eef-1B.2 Antibody

What is EEF1B2 and what are its key molecular characteristics?

EEF1B2 (also known as EEF1B, EF1B, or Elongation factor 1-beta) is a crucial component of the eEF1H complex involved in translation elongation. It functions as a guanine nucleotide exchange factor (GEF) for eEF1A, facilitating the exchange of GDP for GTP, which is essential for the delivery of aminoacyl-tRNAs to the ribosome .

Key characteristics:

• Calculated molecular weight: 24-29 kDa

• Observed molecular weight: 30-34 kDa on SDS-PAGE

• Gene ID (NCBI): 1933

• UniProt ID: P24534

EEF1B2 operates as part of a multiprotein complex (eEF1H) that consists of three subunits: eEF1Bα, eEF1Bβ, and eEF1Bγ. While all three subunits contribute to the complex's function, EEF1B2 specifically possesses the nucleotide-exchange activity .

How should researchers select between different EEF1B2 antibodies?

When selecting an EEF1B2 antibody, researchers should consider multiple factors based on their experimental needs:

Selection criteria should include:

• Experimental application (Western blot, IHC, IF, IP)

• Need for monoclonal specificity versus polyclonal sensitivity

• Validation status (especially knockout validation)

• Species reactivity relevant to your experimental model

• Published literature using the antibody for similar applications

What are the optimized protocols for Western blotting with EEF1B2 antibodies?

For optimal Western blot results with EEF1B2 antibodies, researchers should follow these methodological considerations:

• Sample preparation:

  • Use fresh lysates from cell lines with known EEF1B2 expression (HeLa, HEK-293, Jurkat cells show strong expression)

  • Load 25-30 μg of total protein per lane for cell lines

• Electrophoresis conditions:

  • Use 12% SDS-PAGE gels for optimal resolution around 30-34 kDa

  • Include molecular weight markers that clearly distinguish the 25-35 kDa range

• Transfer and blocking:

  • Standard PVDF or nitrocellulose membranes

  • Block with 3% nonfat dry milk in TBST (shown to be effective in published protocols)

• Antibody dilutions:

  • 10483-1-AP: 1:500-1:2000 for WB

  • 60329-1-Ig: 1:2000-1:10000 for WB

  • A6580: 1:500-1:2000 for WB

  • 10095-2-AP: 1:2000-1:10000 for WB

• Detection:

  • Use HRP-conjugated secondary antibodies (e.g., HRP Goat Anti-Rabbit IgG at 1:10000)

  • ECL detection with 30-90 seconds exposure typically provides clear bands

• Expected results:

  • Primary band at 30-34 kDa representing EEF1B2

  • Validation using EEF1B2 knockout cell lysates is highly recommended

How can researchers optimize immunohistochemistry protocols for EEF1B2 detection?

For successful immunohistochemical detection of EEF1B2 in tissue samples:

• Tissue preparation:

  • Paraffin-embedded samples are suitable for all tested antibodies

  • Multiple tissue types show EEF1B2 expression, with particularly strong signal in pancreas, brain, and colon tissues

• Antigen retrieval:

  • TE buffer at pH 9.0 is the preferred method

  • Alternative: citrate buffer at pH 6.0 if TE buffer gives suboptimal results

• Antibody dilutions:

  • 10483-1-AP: 1:20-1:200 for IHC

  • 10095-2-AP: 1:250-1:1000 for IHC

  • ab228642: 1:500 for IHC-P

• Expected staining patterns:

  • Primarily cytoplasmic localization

  • Strong neuronal staining in brain and spinal cord

  • Intense staining throughout pancreatic islets

  • Variable expression in different cell types within the same tissue

• Controls:

  • Include tissue samples known to be positive for EEF1B2 (pancreatic tissue is ideal)

  • Consider using tissues from EEF1B2 knockout models if available

What considerations are important for immunoprecipitation experiments with EEF1B2 antibodies?

For successful immunoprecipitation of EEF1B2:

• Antibody selection:

  • 10095-2-AP has been validated for IP applications with Jurkat cells

  • 10483-1-AP has been cited in publications for IP applications

• Protocol optimization:

  • Use 0.5-4.0 μg of antibody for 1.0-3.0 mg of total protein lysate

  • Pre-clear lysates to reduce non-specific binding

  • Consider using magnetic beads coated with protein A/G for efficient capture

• Experimental controls:

  • Include isotype control antibodies to detect non-specific binding

  • Use lysates from cells where EEF1B2 has been knocked down as negative controls

• Co-immunoprecipitation applications:

  • EEF1B2 interacts with other eEF1B subunits and eEF1A

  • Both eEF1A1 and eEF1A2 have been shown to interact with EEF1B subunits, though with different affinities

  • Consider proximity ligation assays as complementary approaches to detect these interactions in situ

How can researchers investigate the differential interactions between EEF1B2 and the eEF1A isoforms?

EEF1B2 shows different interaction patterns with the two isoforms of eEF1A (eEF1A1 and eEF1A2), which has significant implications for research design:

• Background on differential interactions:

  • Initial yeast two-hybrid studies suggested eEF1A2 has little or no affinity for eEF1Bα and eEF1Bδ compared to eEF1A1

  • This was unexpected since eEF1A1 and eEF1A2 are 92% identical in amino acid sequence

  • More recent proximity ligation assays (PLA) have demonstrated that eEF1A2 does co-localize with eEF1B subunits in mammalian cells

• Methodological approaches:

  • Proximity Ligation Assay (PLA): This technique can detect protein-protein interactions in fixed cells with high specificity

    • Has successfully shown interaction between eEF1A2 and all three eEF1B subunits in HeLa cells

    • Requires specific antibodies against each protein of interest

    • Include appropriate negative controls (no antibody, single antibody only, or irrelevant antibody pairs)

  • Tagged protein expression:

    • Cell lines stably expressing V5-tagged eEF1A1 or eEF1A2 can help distinguish between the two isoforms

    • Allows for unambiguous identification of interactions when antibodies may cross-react

  • Co-immunoprecipitation:

    • Can be used to pull down eEF1A isoforms and detect associated eEF1B subunits

    • Use V5-tagged constructs or isoform-specific antibodies for clear distinction

    • Quantify interaction strengths between different combinations

• Experimental considerations:

  • Cell type selection is crucial as expression of eEF1A isoforms is tissue-specific

  • eEF1A1 is nearly ubiquitous, while eEF1A2 is expressed primarily in neurons, muscle, and certain cancer cells

  • Consider using neuronal cell lines which naturally express eEF1A2

What are the tissue-specific and developmental considerations for EEF1B2 research?

EEF1B2 expression varies significantly across tissues and developmental stages, which researchers should consider when designing experiments:

• Tissue-specific expression patterns:

  • All eEF1B subunits are expressed in most tissues but at varying levels

  • Particularly high expression in pancreas

  • Lower expression of eEF1Bα in brain, spinal cord, heart, lung, and muscle

  • eEF1Bγ is weakly expressed in muscle but highly expressed in pancreas

• Developmental regulation:

  • eEF1Bα is barely detectable before birth but increases postnatally

  • eEF1Bδ shows higher expression at E15.5 and P2 than at later stages in both liver and brain

  • eEF1Bδ long isoform (eEF1BδL) is expressed in brain at all ages with slight increase with age

• Isoform considerations:

  • The 72 kDa form of eEF1Bδ (eEF1BδL) is expressed primarily in brain, spinal cord, and testis

  • Other eEF1Bδ isoforms (32-38 kDa) are most strongly expressed in liver, pancreas, spleen, and thymus

• Methodological implications:

  • Select appropriate tissue controls based on known expression patterns

  • Consider developmental stage when working with embryonic or neonatal samples

  • Use antibodies that can distinguish between isoforms when studying specific variants

  • Plan sampling timepoints carefully in developmental studies

How should researchers address variability in observed molecular weight for EEF1B2?

The discrepancy between calculated (24-29 kDa) and observed (30-34 kDa) molecular weights for EEF1B2 can cause confusion in data interpretation:

• Causes of molecular weight variability:

  • Post-translational modifications (particularly phosphorylation)

  • Tissue-specific or cell-specific processing

  • Slightly different migration patterns depending on gel percentage and running conditions

  • Presence of splice variants or isoforms

• Methodological approaches to address this issue:

  • Always include positive controls with known EEF1B2 expression (e.g., HeLa or HEK-293 cells)

  • Run knockout or knockdown samples as negative controls when possible

  • Consider using gradient gels (10-15%) for better resolution around the 25-35 kDa range

  • When possible, confirm identity using mass spectrometry

• Interpretation guidelines:

  • The consistent observation across multiple antibodies and studies is a band at 30-34 kDa

  • Band intensity may vary by tissue type, with particularly strong signals in pancreatic tissues

  • Multiple bands may represent different phosphorylation states or splice variants

What controls are essential when investigating EEF1B2 function through knockdown or knockout approaches?

When studying EEF1B2 function through depletion methods:

• Critical experimental controls:

  • Knockdown validation: Confirm reduction of EEF1B2 at both mRNA and protein levels

  • Specificity controls: Monitor potential effects on other eEF1B subunits, as downregulation of one subunit can affect expression of others

  • Rescue experiments: Re-express EEF1B2 to confirm phenotype reversal

  • Multiple siRNA sequences: Use at least two independent siRNA sequences to rule out off-target effects

• Functional readouts to consider:

  • Cell viability: Downregulation of eEF1B subunits has been shown to reduce cell viability by at least 20% in some cell lines

  • Protein synthesis rates: Measure global translation through metabolic labeling or polysome profiling

  • GEF activity: Assess nucleotide exchange on eEF1A using purified components

• Interpretation challenges:

  • Effects on cell viability may not be specific to EEF1B2 function in translation

  • Compensatory mechanisms may mask phenotypes in short-term experiments

  • Different cell types show varying sensitivity to EEF1B2 depletion

How can researchers distinguish between different EEF1B subunits in their experimental systems?

The eEF1B complex consists of three subunits (eEF1Bα, eEF1Bβ, and eEF1Bγ) that can be challenging to distinguish:

• Antibody selection strategies:

  • Use antibodies raised against unique regions of each subunit

  • Verify specificity using overexpression and knockout/knockdown systems

  • Consider the molecular weight differences:

    • eEF1Bα: ~26-30 kDa

    • eEF1Bβ/EEF1B2: ~30-34 kDa

    • eEF1Bγ: ~50 kDa

    • eEF1BδL (long isoform): ~72 kDa

• Experimental approaches for subunit identification:

  • Sequential immunoprecipitation: Pull down one subunit first, then probe for co-precipitated subunits

  • Mass spectrometry: Identify unique peptides that differentiate between subunits

  • Tissue expression patterns: Leverage known differences in expression patterns (e.g., eEF1BδL is primarily in brain, spinal cord, and testis)

• Functional differentiation:

  • eEF1Bα and eEF1Bβ have GEF activity for eEF1A

  • eEF1Bγ lacks GEF activity but may have structural or regulatory roles

  • The functions of specific isoforms (like eEF1BδL) may be tissue-specific

How can EEF1B2 antibodies be utilized in virus-host interaction studies?

Recent research has implicated EEF1 complex components in viral replication processes:

• Role in viral protein translation:

  • eEF1G (another eEF1 complex component) plays a role in the translation of viral proteins in a strain-specific manner

  • This suggests potential strain-specific roles for other components of the complex, including EEF1B2

• Experimental approaches:

  • Viral infection models: Compare EEF1B2 expression and localization in infected versus uninfected cells

  • Co-immunoprecipitation: Identify viral proteins that interact with EEF1B2

  • Knockdown/knockout studies: Determine if EEF1B2 depletion affects viral replication

• Technical considerations:

  • Use antibodies validated for immunofluorescence to track localization changes during infection

  • Consider proximity ligation assays to detect interactions between EEF1B2 and viral proteins

  • Include appropriate controls to distinguish direct effects from general translation inhibition

What considerations are important when using EEF1B2 antibodies in cancer research applications?

EEF1B2 and other translation factors have gained attention in cancer research:

• Expression in cancer tissues:

  • EEF1B2 antibodies have been validated on various cancer tissues, including colon cancer, breast cancer, and pancreatic cancer

  • 10095-2-AP and other antibodies have been used successfully for IHC on cancer tissues

• Methodological approaches for cancer studies:

  • Tissue microarrays: Compare EEF1B2 expression across multiple cancer types and stages

  • Patient-derived xenografts: Antibodies like ab228642 have been tested on xenograft models (U87 xenograft)

  • Cancer cell line panels: Evaluate expression across established cancer cell lines like HeLa, MCF-7, and PC-3

• Technical considerations:

  • Optimize antigen retrieval methods for each cancer tissue type

  • Include normal adjacent tissue controls

  • Consider dual-staining with cancer-specific markers to identify cell populations with altered EEF1B2 expression